DK155568C - Fremgangsmaade til stabilisering af koagulationsfaktorerne ii, viii, xiii og antithrombin iii samt plasminogen, og saaledes at disse er fibrinogen-fri og fri for risiko for en hepatitis-overfoering - Google Patents

Fremgangsmaade til stabilisering af koagulationsfaktorerne ii, viii, xiii og antithrombin iii samt plasminogen, og saaledes at disse er fibrinogen-fri og fri for risiko for en hepatitis-overfoering

Info

Publication number
DK155568C
DK155568C DK176280A DK176280A DK155568C DK 155568 C DK155568 C DK 155568C DK 176280 A DK176280 A DK 176280A DK 176280 A DK176280 A DK 176280A DK 155568 C DK155568 C DK 155568C
Authority
DK
Denmark
Prior art keywords
free
xiii
viii
stabilizing
plasminogen
Prior art date
Application number
DK176280A
Other languages
Danish (da)
English (en)
Other versions
DK176280A (da
DK155568B (da
Inventor
Horst Schwinn
Norbert Heimburger
Gerhardt Kumpe
Bernd Herchenhan
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of DK176280A publication Critical patent/DK176280A/da
Publication of DK155568B publication Critical patent/DK155568B/da
Application granted granted Critical
Publication of DK155568C publication Critical patent/DK155568C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A61L2103/05—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/851—Placenta; amniotic fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK176280A 1979-04-25 1980-04-24 Fremgangsmaade til stabilisering af koagulationsfaktorerne ii, viii, xiii og antithrombin iii samt plasminogen, og saaledes at disse er fibrinogen-fri og fri for risiko for en hepatitis-overfoering DK155568C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2916711 1979-04-25
DE19792916711 DE2916711A1 (de) 1979-04-25 1979-04-25 Blutgerinnungsfaktoren und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
DK176280A DK176280A (da) 1980-10-26
DK155568B DK155568B (da) 1989-04-24
DK155568C true DK155568C (da) 1989-10-09

Family

ID=6069217

Family Applications (1)

Application Number Title Priority Date Filing Date
DK176280A DK155568C (da) 1979-04-25 1980-04-24 Fremgangsmaade til stabilisering af koagulationsfaktorerne ii, viii, xiii og antithrombin iii samt plasminogen, og saaledes at disse er fibrinogen-fri og fri for risiko for en hepatitis-overfoering

Country Status (8)

Country Link
US (1) US4297344A (index.php)
EP (1) EP0018561B1 (index.php)
JP (1) JPS55145615A (index.php)
AT (1) ATE22396T1 (index.php)
DE (2) DE2916711A1 (index.php)
DK (1) DK155568C (index.php)
ES (1) ES8100884A1 (index.php)
IL (1) IL59924A (index.php)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
IT1194135B (it) * 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
EP0286198B1 (en) * 1981-04-27 1994-12-14 BAXTER INTERNATIONAL INC. (a Delaware corporation) Blood clotting enzyme compositions
US4480029A (en) * 1981-04-27 1984-10-30 Baxter Travenol Laboratories, Inc. Biological indicators and their use
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
DE3119157A1 (de) * 1981-05-14 1982-12-09 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von und danach hergestelltes plasminogen
EP0081482A1 (en) * 1981-06-18 1983-06-22 E. G. Birger Blombäck A process in purification and concentration of the factor viii complex
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4845074A (en) * 1982-05-13 1989-07-04 Cedars Sinai Medical Center Heat treatment of Factor VIII
US4556558A (en) * 1982-05-13 1985-12-03 Cedars-Sinai Medical Center Treatment of factor VIII concentrate to minimize the affect of undesirable microorganisms
DE3230849A1 (de) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
DE3473407D1 (en) * 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
AT376881B (de) * 1983-05-02 1985-01-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern
DE3481109D1 (de) * 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
HUT40311A (en) * 1983-06-03 1986-12-28 Kiskunhalasi Aag Process for producing protein concentrates, blood-curd and nutriments from blood and its elements
DE3330770A1 (de) * 1983-08-26 1985-03-14 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von humanplasma
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
AT390001B (de) * 1984-09-28 1990-03-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
DE3602688A1 (de) * 1986-01-30 1987-08-06 Behringwerke Ag Verfahren zur gewinnung und herstellung eines pasteurisierten praeparates von (alpha)(pfeil abwaerts)2(pfeil abwaerts)-antiplasmin
DE3621371A1 (de) * 1986-03-12 1987-09-17 Behringwerke Ag Gentechnische herstellung von faktor xiiia
JPH0725696B2 (ja) * 1986-05-29 1995-03-22 株式会社ミドリ十字 プラスミノ−ゲンの安定化方法
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
CA1310267C (en) * 1986-07-09 1992-11-17 Yutaka Hirao Process for heat treating chemically unmodified _-globulin
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
DE3625090A1 (de) * 1986-07-24 1988-01-28 Behringwerke Ag Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
WO1989001512A1 (en) * 1987-08-17 1989-02-23 The Liposome Company, Inc. A sponge enzyme having transglutaminase-like activity
DK18288D0 (da) * 1988-01-15 1988-01-15 Nordisk Gentofte Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
FR2650508A1 (fr) * 1989-08-01 1991-02-08 Fondation Nale Transfusion San Colle pasteurisee pour reunir des tissus humain ou animal
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤
JPH0813750B2 (ja) * 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
FR2664165B1 (fr) 1990-07-03 1992-10-16 Lille Transfusion Sanguine Composition pour stabiliser le plasma sanguin en cours de pasteurisation.
US5314695A (en) † 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
WO1994013329A1 (de) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
NZ262634A (en) * 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
CA2137258A1 (en) * 1993-04-05 1994-10-13 Yoshitomi Pharmaceutical Industries Ltd. Liquid preparation of antithrombin-iii and stabilizing method therefor
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
WO1996002571A1 (fr) * 1994-07-14 1996-02-01 Croix-Rouge De Belgique Concentre de fibrinogene issu de plasma sanguin, procede et installation pour sa preparation
WO1997003706A1 (fr) 1995-07-14 1997-02-06 Croix-Rouge De Belgique Procede et installation d'inactivation de contaminants presents dans des produits sanguins
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6399296B1 (en) * 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
JP3651003B2 (ja) * 1994-10-11 2005-05-25 味の素株式会社 安定化されたトランスグルタミナーゼ及びそれを含む酵素製剤
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
JPH08333277A (ja) * 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
DE69733664T3 (de) * 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
EP0844254A3 (en) * 1996-11-20 1999-05-12 The Green Cross Corporation Method for producing antithrombin-III, method for purifying it, and preparation containing it
GB9711927D0 (en) * 1997-06-09 1997-08-06 Bristol Myers Squibb Co Compositions useful as fibrin sealants
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
AT407484B (de) * 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
CA2728907C (en) 1998-08-06 2015-11-24 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
DE19856443A1 (de) * 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
ES2541470T3 (es) * 1999-02-22 2015-07-20 University Of Connecticut Formulaciones de factor VIII libres de albúmina
US6733985B1 (en) * 1999-05-19 2004-05-11 International Technidyne Corporation Preparation of stable liquid and dried synthetic prothrombin time reagents
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
EP2368898B1 (en) 1999-11-18 2014-10-01 Ischemix, Inc Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
PL356801A1 (en) 2000-01-28 2004-07-12 Aventis Pharma Deutschland Gmbh Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
IL152360A0 (en) 2000-04-19 2003-05-29 Genentech Inc Sustained release formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20020176796A1 (en) * 2000-06-20 2002-11-28 Purepulse Technologies, Inc. Inactivation of microbes in biological fluids
JP2002112765A (ja) * 2000-08-01 2002-04-16 Nihon Pharmaceutical Co Ltd ウイルス不活化法
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
JP4724354B2 (ja) * 2001-02-23 2011-07-13 ジェネンテック， インコーポレイテッド 注射用の崩壊性ポリマー
WO2002092781A2 (en) * 2001-05-17 2002-11-21 Ceremedix, Inc. Peptide compounds for counteracting reactive oxygen species and free radicals
DK1397155T3 (en) * 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
RU2004122430A (ru) * 2001-12-21 2005-04-20 Ново Нордиск А/С (DK) Жидкая композиция полипептидов модифицированного фактора vii
JP2005530683A (ja) * 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
WO2004082708A2 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US7498130B2 (en) * 2003-05-13 2009-03-03 Massachusetts General Hospital Method of reducing viral load
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
CA2525224A1 (en) * 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN1845753A (zh) 2003-08-14 2006-10-11 诺和诺德医疗保健公司 因子ⅶ多肽类的含水液体药物组合物
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
RU2435847C2 (ru) 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
PT3321359T (pt) 2005-04-11 2021-03-11 Horizon Pharma Rheumatology Llc Formas variantes de urato-oxidase e a sua utilização
US20090081122A1 (en) * 2005-05-23 2009-03-26 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
DE602006018622D1 (de) * 2005-06-30 2011-01-13 Ge Healthcare Bio Sciences Nachweisverfahren für die genexpression
KR101288027B1 (ko) 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
WO2009130181A2 (en) * 2008-04-21 2009-10-29 Novo Nordisk Health Care Ag Dry transglutaminase composition
BRPI0920973B8 (pt) 2008-11-04 2021-05-25 Aska Pharm Co Ltd composição aquosa contendo hormônio estimulanete de folículos
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
EP2446260B1 (en) 2009-06-25 2018-12-26 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CA2792965A1 (en) 2010-04-27 2011-11-03 Scil Technology Gmbh Stable aqueous mia/cd-rap formulations
IL213864A0 (en) 2011-06-30 2011-08-31 Omrix Biopharmaceuticals Ltd Method for removing a lytic enzyme from a heterogeneous mixture
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
RU2556804C2 (ru) * 2013-12-17 2015-07-20 Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ Способ получения концентрата фибриногена
IL231230A0 (en) 2014-02-27 2014-08-31 Omrix Biopharmaceuticals Ltd Fibrinogen preparation
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
UA123496C2 (uk) * 2014-12-19 2021-04-14 Прометік Байо Терап'Ютікс, Інк. Фармацевтична композиція, що містить плазміноген, та її застосування
IL247821A0 (en) 2016-09-14 2017-01-31 Omrix Biopharmaceuticals Ltd Adhesive preparations and their use
JP2019535819A (ja) 2016-11-11 2019-12-12 ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
EP3770254A4 (en) * 2018-03-23 2021-12-29 Ajinomoto Co., Inc. Liquid preparation containing transglutaminase
WO2019201894A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
WO2020121289A1 (en) 2018-12-12 2020-06-18 Omrix Biopharmaceuticals Ltd. Low concentrated protein compositions for preventing tissue adhesion
IL263679A (en) 2018-12-12 2019-03-31 Omrix Biopharmaceuticals Ltd Kits, methods, and compositions for preventing tissue adhesion
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US20250073313A1 (en) 2021-12-21 2025-03-06 Omrix Biopharmaceuticals Ltd. Highly soluble fibrinogen compositions
AU2022426762A1 (en) 2021-12-30 2024-07-04 Baxter Healthcare Sa Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3066079A (en) * 1959-09-18 1962-11-27 American Cyanamid Co Methods for purifying plasminogen
GB941019A (en) * 1961-04-27 1963-11-06 Crookes Lab Ltd Improvements in and relating to the stability of anti-haemophilic globulin (factor viii)
US3227626A (en) * 1961-09-18 1966-01-04 Merck & Co Inc Plasminogen heat sterilization
CA958339A (en) * 1970-09-19 1974-11-26 Yoshio Yoshimura Stabilization of microorganism cells lytic enzyme
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US3732146A (en) * 1970-12-22 1973-05-08 Behringwerke Ag Process for the isolation of native, highly purified plasminogen
SE392038B (sv) 1971-09-08 1977-03-14 Kabi Ab Forfarande for isolering av antitrombin ur blod eller blodprodukter
JPS5226255B2 (index.php) * 1973-05-07 1977-07-13
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
JPS51118820A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable macroglobulin
DE2653534C2 (de) * 1975-12-22 1986-08-28 Baxter Travenol Laboratories, Inc., Deerfield, Ill. Feste Antihämophilen-Faktor-Präparation und Verfahren zu ihrer Herstellung
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
JPH05118819A (ja) * 1991-10-29 1993-05-14 Toshiba Corp 視覚認識装置

Also Published As

Publication number Publication date
ES490682A0 (es) 1980-12-01
JPS55145615A (en) 1980-11-13
ES8100884A1 (es) 1980-12-01
JPS6254286B2 (index.php) 1987-11-13
EP0018561A3 (en) 1981-10-21
DE2916711A1 (de) 1980-11-06
DE3071773D1 (en) 1986-10-30
IL59924A0 (en) 1980-06-30
IL59924A (en) 1983-06-15
EP0018561A2 (de) 1980-11-12
EP0018561B1 (de) 1986-09-24
ATE22396T1 (de) 1986-10-15
US4297344A (en) 1981-10-27
DK176280A (da) 1980-10-26
DK155568B (da) 1989-04-24

Similar Documents

Publication Publication Date Title
DK155568C (da) Fremgangsmaade til stabilisering af koagulationsfaktorerne ii, viii, xiii og antithrombin iii samt plasminogen, og saaledes at disse er fibrinogen-fri og fri for risiko for en hepatitis-overfoering
BR8207582A (pt) Processo para producao de novas composicoes de enzima para coagulacao sang"uinea
DK160459C (da) Fremgangsmaade til fremstilling af denatureringsbestandige vandige proteinoploesninger
DK542785D0 (da) Fremgangsmaade til fremstilling af 7-halogen-7-deoxylincomycin eller dermed analoge forbindelser
FI831228L (fi) Framstaellning av funktionellt maenskligt urokinasprotein
DK417387D0 (da) Fremgangsmaade til raffinering af glasagtigt materiale
DE68924267D1 (de) Stabilisierung von polyarylenetherketonen.
BG37376A3 (en) Method for preparing salts of benzothiazine dioxide
DK406184D0 (da) Fremgangsmaade til pasteurisering af humanplasma
DK185979A (da) Reagens til bestemmelse af hepatitis b, dets fremstilling og anvendelse
DK291584D0 (da) Stabilisering af smeltekrystallisationstemperatur ved varmebehandling af arylensulfidpolymer
DK155953C (da) Fremgangmsaade til stabilisering af peroxidase i et flydende medium og saaledes stabiliseret medium
SE8800249D0 (sv) Magnetisk krets
DK500179A (da) 4,1-benzoxazepiner og thia-analoge samt fremgangsmaade til fremstilling deraf
DK723488A (da) Fremgangsmaade til rekombinant udtrykkelse af zymogene former af humant protein c samt vektorer, dna-forbindelser og transformanter til brug ved fremgangsmaaden
DK408183A (da) Fremgangsmaade til fremstilling af 2-(5,5-disubstitueret 4-oxo-2-imidazolin-2-yl)-nicotinsyrer og quinolin-3-carboxylsyrer
DK585984D0 (da) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan og salte deraf til anvendelse ved bekaempelse af sygdomme samt fremgangsmaade til fremstilling af saadanne nonanderivater
NO160864C (no) Fremgangsmaate til fremstilling av et varmebehandlet nikkel-jern-basert legeringsprodukt.
DK179784A (da) Krystallinsk zinksilicat, fremgangsmaade til dets fremstilling samt dets anvendelse
DK165022C (da) Varmepumpe, der energiforsynes af en lavtemperaturvarmekilde og fremgangsmaade, ved hvilken en lavtemperaturvarmekilde anvendes til opvarmning og afkoeling
DK432879A (da) Fremgangsmaade til oparbejdning af biomasser,modificerede biomasser og deres anvendelse
DK192890D0 (da) 24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme
NO152883C (no) Hoeytemperaturbrenner og fremgangsmaate ved drift av saadan.
DK158142C (da) Fremgangsmaade til beskyttelse af trae og traebeskyttelsesmiddel til anvendelse derved
DK150853C (da) Fremgangsmaade til fremstilling af 6-chlor-benzoxazolon

Legal Events

Date Code Title Description
PUP Patent expired